Recombinant Human SLC2A1 protein

中文名： 溶质载体家族2，促进葡萄糖转运蛋白成员1(SLC2A1)重组蛋白
别名： SLC2A1；GLUT1；Solute carrier family 2, facilitated glucose transporter member 1

货号: PA2000-2216

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	SLC2A1
Uniprot No	P11166
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	207-271aa
氨基酸序列	CPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQP
预测分子量	15.2 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于SLC2A1重组蛋白的3篇代表性文献示例(注：文献为虚构示例，实际引用请核实真实来源)：

1. **标题**：*Expression and Functional Characterization of Recombinant Human SLC2A1/GLUT1 in HEK293 Cells*

**作者**：Smith A, et al.

**摘要**：本研究利用哺乳动物表达系统成功表达了重组SLC2A1蛋白，并通过放射性葡萄糖摄取实验证实其功能性，为体外研究GLUT1的转运机制提供了可靠工具。

2. **标题**：*Cryo-EM Structure of Recombinant GLUT1 Reveals Substrate Binding Sites*

**作者**：Chen L, et al.

**摘要**：通过冷冻电镜解析了重组GLUT1蛋白的高分辨率结构，揭示了葡萄糖结合的关键氨基酸残基及构象变化，为设计靶向GLUT1的抑制剂奠定结构基础。

3. **标题**：*Recombinant SLC2A1 Mutants in GLUT1 Deficiency Syndrome Modeling*

**作者**：Wang Y, et al.

**摘要**：构建了携带致病突变的重组SLC2A1蛋白，发现特定突变导致葡萄糖转运效率下降超50%，解释了GLUT1缺乏综合征的分子机制。

如需真实文献，建议在PubMed中以关键词 **"SLC2A1 recombinant protein"** 或 **"GLUT1 expression purification"** 检索近年研究。

背景信息

**Background of SLC2A1 Recombinant Protein**

The SLC2A1 gene encodes glucose transporter 1 (GLUT1), a critical membrane protein responsible for facilitating the passive transport of glucose across cell membranes. As a member of the solute carrier 2 (SLC2) family, GLUT1 is ubiquitously expressed but particularly vital in tissues with high metabolic demands, such as the brain, erythrocytes, and the blood-brain barrier (BBB). It ensures a constant supply of glucose, the primary energy substrate for cellular metabolism, maintaining homeostasis in energy-sensitive environments.

SLC2A1 recombinant protein is engineered using biotechnology techniques to produce a purified, functional form of GLUT1 for research and therapeutic applications. This involves cloning the SLC2A1 gene into expression systems (e.g., bacterial, mammalian, or insect cells) to synthesize the protein, followed by purification via affinity chromatography. The recombinant product retains the structural and functional features of native GLUT1. including its 12 transmembrane domains and substrate-binding specificity.

Studying SLC2A1 recombinant protein has advanced understanding of glucose transport mechanisms and metabolic disorders. Mutations in SLC2A1 are linked to GLUT1 deficiency syndrome (GLUT1DS), a rare neurological disorder characterized by impaired glucose transport into the brain, leading to seizures and developmental delays. Recombinant GLUT1 aids in developing diagnostic assays and evaluating therapeutic interventions. Additionally, its role in cancer metabolism is under scrutiny, as many tumors overexpress GLUT1 to fuel rapid proliferation via the Warburg effect.

In drug discovery, SLC2A1 recombinant protein serves as a target for inhibitors aimed at curbing cancer growth or modulators for metabolic diseases. Its application extends to structural studies, antibody production, and functional assays to dissect transport kinetics or ligand interactions. Overall, this recombinant tool bridges molecular research with clinical innovation, offering insights into both fundamental biology and disease pathology.